Trials / Terminated
TerminatedNCT05601219
A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multicenter Study of ADA-011 as Monotherapy and in Combination With a Checkpoint Inhibitor for Subjects With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Adanate, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study consists of dose escalation evaluation to determine the safety and tolerability of ADA-011 as a monotherapy. Following dose escalation, one or more dose expansion cohorts in selected indications will be explored to further evaluate the safety, tolerability, and preliminary efficacy of ADA-011.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADA-011 | ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle. |
| DRUG | PD(L)-1 inhibitor | PD(L)-1 inhibitor will be administered intravenously (IV) Q3W. |
Timeline
- Start date
- 2022-11-15
- Primary completion
- 2024-10-30
- Completion
- 2024-10-30
- First posted
- 2022-11-01
- Last updated
- 2025-01-28
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05601219. Inclusion in this directory is not an endorsement.